Company profile
Foghorn Therapeutics Inc.
NASDAQ: FHTX · Healthcare · Biotechnology
#499 of 1,418 Healthcare companies by revenue74th-percentile growth
EA Score
47DFH 34DQ 62GM 51SS 55
v0.1 · 65/100 weight · provisional
↑ filing timeliness, revenue growth (YoY) · ↓ Piotroski F, growth stability
Methodology →Revenue TTM
$36.7M
Rev growth YoY (TTM)
+52.0%
Net income (FY)
-$74.3M
Employees
106
as of 2026-08-13
Market cap
$389.9M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$30.9M$30.9M2025
Net income-$74.3M-$74.3M2025
Operating income-$86.4M-$86.4M2025
Total assets$198.1M$198.1M2025
Liabilities$306.6M$306.6M2025
Equity-$108.5M-$108.5M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Foghorn Therapeutics Inc.’s revenue?
Foghorn Therapeutics Inc. booked $30.9M in FY2025 revenue, growing 37% year over year — faster than most Healthcare companies we track, at a -240.3% net margin.
Peers · Healthcare
Cryo-Cell International, Inc.63CEyePoint Pharmaceuticals, Inc.58CVerastem, Inc.49DScripsAmerica, Inc.——BioSyent Inc.83B+STRATA Skin Sciences, Inc.52DNeighbors
Middlesex →Key facts
CEOAdrian H. Gottschalk
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: FHTX
Employees106
IPO date2020-10-23
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.